Lyrica
Product Images NDC 16590-503

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 16590-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lyrica 50 mg)

LYRICA C-V 50 mg capsule blister card, packaged and distributed by STAT Rx USA LLC. Label shows dosing strength of 50 mg pregabalin per capsule, package count of 60 capsules, and includes NDC 16590-503-60. Additional information includes lot number, expiration date, manufacturing details by Pfizer Pharm. LLC in Vega Baja, PR, and a warning to keep out of reach of children.*

FDA Label Image

Figure Of The Cockcroft And Gault Equation (Lyrica 1)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine level, and sex, shown in a mathematical expression. The formula includes adjustment for female patients by multiplying by 0.85.*

FDA Label Image

Figure 8: Patients Achieving Various Levels Of Pain Relief – Fibromyalgia Study F1 (Lyrica 10)

A line chart comparing the percent improvement in pain from baseline against the percent of patients improved for LYRICA (pregabalin) at 300 mg, 450 mg, and 600 mg daily doses, plus placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved. Four lines represent the different dose groups and placebo for comparison.*

FDA Label Image

Figure 9: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (Lyrica 11)

A survival curve line graph comparing the estimated percentage of subjects without LTR over days for Pregabalin versus placebo groups. The y-axis represents the percentage of subjects without LTR ranging from 0% to 100%, and the x-axis represents the duration in days, up to 180 days. The graph shows Pregabalin's line higher above placebo throughout the timeline, indicating a greater percentage of subjects without LTR.*

FDA Label Image

The Chemical Structure Of Pregabalin. (Lyrica 2)

Chemical structure diagram of pregabalin, the active ingredient in LYRICA, showing its molecular arrangement with labeled carbon, nitrogen, oxygen atoms, and functional groups.*

FDA Label Image

Figure 1: Patients Achieving Various Levels Of Pain Relief – Study Dpn 1 (Lyrica 3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for LYRICA (pregabalin) at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The graph illustrates greater patient improvement with higher pregabalin doses compared to placebo.*

FDA Label Image

Figure 2: Patients Achieving Various Levels Of Pain Relief – Study Dpn 2 (Lyrica 4)

A line graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares two lines labeled Pregabalin 100 mg three times a day and Placebo over the range of pain improvement percentages.*

FDA Label Image

Figure 3: Patients Achieving Various Levels Of Pain Relief – Study Phn 1 (Lyrica 5)

A line graph displaying the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The chart compares placebo with three dosages of Pregabalin (75 mg, 150 mg, and 300 mg, all taken twice a day), showing trends of patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure 4: Patients Achieving Various Levels Of Pain Relief – Study Phn 2 (Lyrica 6)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends of patient improvement across different pain reduction percentages.*

FDA Label Image

Figure 5: Patients Achieving Various Levels Of Pain Relief – Study Phn 3 (Lyrica 7)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for LYRICA (pregabalin) at two doses, 50 mg and 100 mg taken three times a day, compared to placebo. The horizontal axis indicates percent improvement in pain, while the vertical axis shows the percent of patients improved.*

FDA Label Image

Figure 6. Responder Rate By Add-on Epilepsy Study (Lyrica 8)

A bar chart comparing responder rates in two studies, Study E1 and Study E3. It shows the percentage of responders across various doses and placebo groups, with data points labeled above each bar. The x-axis lists dosage groups and sample sizes, while the y-axis indicates responder rates in percentage from 0 to 60%.*

FDA Label Image

Figure 7. Seizure Reduction By Dose (all Partial Onset Seizures) For Studies E1, E2, And E3 (Lyrica 9)

A dose-response line graph showing seizure reduction (median % change from baseline) on the y-axis and dose in mg/day on the x-axis for LYRICA. The graph compares four studies (E1 BD, E2 TID, E3 BID, E3 TID) with significant p-values indicated for various doses, demonstrating increased seizure reduction with higher doses up to 600 mg/day.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.